Generic Line
Nov. 7, 2012
| Vol.
29 No.
22
Hetero, Forest Reach Deal on Generic of Forest’s Bystolic
Hetero can launch a generic version of Forest Laboratories’ hypertension drug Bystolic three months prior to the expiration of Forest’s exclusivity on Dec. 17, 2021, or on the date it receives final ANDA approval from the agency, whichever is later under the terms of a proposed settlement.
This article is viewable by subscribers only. To view this article, please select an option below.
|